<ul><li>Biocon Biologics, a subsidiary of Biocon Ltd, has received approval from the US Food and Drug Administration (USFDA) for Jobevne (bevacizumab-nwgd), a biosimilar cancer treatment product.</li><li>Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that is used to treat different types of cancer by restricting blood supply to the tumor.</li><li>The approval expands Biocon Biologics' biosimilar oncology portfolio in the US and is their seventh biosimilar approved in the country.</li><li>In 2023, the sales of bevacizumab, the reference product for Jobevne, stood at around USD 2.0 billion in the US.</li></ul>

Biocon Biologics Gets USFDA Approval For Cancer Biosimilar

Discover more